Capecitabine, a prodrug of fluorouracil, is a pyrimidine analogue that can inflame actinic keratoses.1 The inflammation manifests primarily as simple erythema in areas of actinic keratoses, although acral erythema and other cutaneous adverse effects have been reported.1,2 Bevacizumab inhibits angiogenesis by blocking vascular endothelial growth factor and can produce cutaneous adverse effects such as exfoliative dermatitis, skin ulceration, and acneiform eruptons.3 We describe a severe complication resulting from the combination of capecitabine and bevacizumab.
Black JM, Hodari KT, Rogers N, Farris PK, Lewis AT, Boh EE. Exudative, Nonhealing Scalp: A Complication of Systemic Chemotherapy With Capecitabine and Bevacizumab. Arch Dermatol. 2011;147(1):134–135. doi:https://doi.org/10.1001/archdermatol.2010.396
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: